- In September 2024, Sanofi and Regeneron announced plans to seek regulatory approval for Dupixent in the treatment of bullous pemphigoid following positive results from a Phase 3 clinical trial. The companies’ blockbuster anti-inflammatory biologic continues to gain momentum. On the same day, they shared promising data from a study on chronic spontaneous urticaria (CSU) and a new analysis of results in chronic obstructive pulmonary disease (COPD), the pivotal findings in the rare skin condition bullous pemphigoid (BP) pave the way for another regulatory submission
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Bullous Pemphigoid, Cicatricial Pemphigoid, and Pemphigoid Gestationis), Medication Type (Corticosteroids, Anti-Biotics, Steroid-Sparing Immunosuppressant Drugs, and Others), Route of Administration (Oral, Injectable, and Topical), Distribution Channel (Online Pharmacy, Direct Tenders, Retailers, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2032
.
The Global Pemphigoid Drug Market size was valued at USD 181.27 USD Billion in 2024.
The Global Pemphigoid Drug Market is projected to grow at a CAGR of 15.8% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
